There is one clinical trial.
ImmuneSense Lyme is a study, which is designed to better understand the immune response to Lyme disease. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot. De-identified data collected from this study may accelerate the development of better diagnostics for Lyme disease and improve outcomes for many.
Description: Diagnostic sensitivity is defined as the percentage of persons who have a given disorder who are identified by the assay as positive for Lyme disease.Measure: To demonstrate Sensitivity of immunoSEQ Dx Lyme Assay is superior to STTT Time: Baseline
Description: Diagnostic specificity is defined as the percentage of persons who do not have a given condition who are identified by the assay as negative for Lyme disease.Measure: To demonstrate Specificity of immunoSEQ Dx Lyme Assay is noninferior to STTT Time: Baseline
Description: To demonstrate ability of immunoSEQ Dx Lyme Assay to detect Lyme disease over the time at base line, 1 months, 6 months, and 12 monthsMeasure: To demonstrate ability of immunoSEQ Dx Lyme Assay to detect Lyme disease over the time Time: Base line, 30 days, 6 months, 12 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports